title: [Hematologic adverse effects in patients with renal cell carcinoma treated with sunitinib].
abstract: OBJECTIVE
  To explore the hematologic adverse effects in patients with renal cell carcinoma treated with sunitinib.
  
  
  METHODS
  A total of 136 patients with advanced renal cell carcinoma were treated with sunitinib at our hospital from 2008 to 2011. There were 91 males and 45 females with an average age of 55.5 years. They received sunitinib in repeated 6-week cycles consisting of 4 weeks of sunitinib 50 mg per day followed by 2 weeks of treatment (schedule 4/2). The hematologic toxicities, collected at baseline and 14, 28, 42 (after a 2-week rest period) days, were graded according to the National Cancer Institute common terminology criteria for adverse events version 3.0. The paired Wilcoxon test was used to evaluate the kinetics of hematologic adverse effects at days 14, 28, and 42 post-treatment.
  
  
  RESULTS
  The hematologic toxicities included leukopenia (n = 91, 66.9%), neutropenia (n = 95, 69.8%), lymphopenia (n = 58, 46.2%), thrombopenia (n = 89, 65.4%) and hypohemoglobinemia (n = 48, 35.3%). Among them, 31 cases (22.8%) had the high-grade (including grades 3 and 4) toxicity of thrombopenia. There were depressions in hematopoietic cell populations including leukocytes, neutrophils, and platelets at days 14, 28 and 42 versus the baseline level (all P < 0.05). The median hemoglobin level transiently increased at days 14 and 28 (both P < 0.01) and returned to the level of baseline at days 42 (P = 0.754).
  
  
  CONCLUSIONS
  The incidence of hematologic adverse effects of sunitinib slightly varies with what have been observed in previous studies. And the incidence of high-grade toxicity of thrombocytopenia is higher than that reported in studies conducted in the US and Europe.
authors.affiliation: Department of Urology, Fudan University Cancer Hospital, Shanghai, China.
authors.forename: Ya-ping
authors.initials: YP
authors.lastname: Hong
authors.forename: Xu-dong
authors.initials: XD
authors.lastname: Yao
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhu
authors.forename: Shi-lin
authors.initials: SL
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Dai
authors.forename: Hai-liang
authors.initials: HL
authors.lastname: Zhang
authors.forename: Yi-jun
authors.initials: YJ
authors.lastname: Shen
authors.forename: Yi-ping
authors.initials: YP
authors.lastname: Zhu
authors.forename: Chun-guang
authors.initials: CG
authors.lastname: Ma
authors.forename: Wen-jun
authors.initials: WJ
authors.lastname: Xiao
authors.forename: Xiao-jian
authors.initials: XJ
authors.lastname: Qin
authors.forename: Guo-wen
authors.initials: GW
authors.lastname: Lin
authors.forename: Ding-wei
authors.initials: DW
authors.lastname: Ye
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use / Q000633:toxicity*; D007680:Kidney Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011758:Pyrroles / Q000627:therapeutic use / Q000633:toxicity*; D012189:Retrospective Studies; D000077210:Sunitinib; D055815:Young Adult
chemical_list: D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib